1 / 12

Data Protection, USMCA and Spending on Biologics in Canada

Data Protection, USMCA and Spending on Biologics in Canada. Joel Lexchin MD Professor Emeritus, York University Associate Professor, University of Toronto Emergency Physician, University Health Network. Data Protection in Canada. Requirements for data protection

zariel
Download Presentation

Data Protection, USMCA and Spending on Biologics in Canada

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Data Protection, USMCA and Spending on Biologics in Canada Joel Lexchin MD Professor Emeritus, York University Associate Professor, University of Toronto Emergency Physician, University Health Network

  2. Data Protection in Canada • Requirements for data protection • Drug contains a medicinal ingredient never sold before in Canada • Data should have required considerable effort to generate, where considerable effort is defined as the use of clinical trials to produce the data • Currently • Data protected for 6 years after brand-name drug is marketed and Health Canada will not approve a generic/biosimilar until 8 years after brand-name drug marketed (extra 6 months if pediatric trials done) • Data protection cannot be challenged in court unlike patent protection

  3. USMCA • Adds 2 more years to data protection for biologics, i.e., 10 years of market protection for biologics from biosimilars • Will only apply to biologics approved once agreement is ratified and comes into effect

  4. Increasing Use of Biologics

  5. How Much Will Spending on Biologics Increase • Estimates based on applying additional 2 years of data protection to existing biologics • Depends on • Whether data protection or patent protection will expire first • Percent of market captured by biosimilars • Discount from biosimilars

  6. Possible Drugs to be Affected by USMCA

  7. Price of Biosimilars Compared to Originators

  8. Biosimilar Uptake in Canada

  9. Top Selling Biologics in Canada

  10. Biologics with Data Protection on Canadian Market • Assumes current mean Canadian price reduction of 26% • Lost savings could be $0 if patents expire later than 10 years of data protection Only 2 of the 17 best selling biologics on the Canadian market currently have data protection (aflibercept and pertuzumab–trastuzumab)

  11. Additional Considerations • From January 1, 1995, to March 31, 2018, 139 biologics approved • 9 had biosimilars • Only 1 biosimilar would have been potentially delayed by additional data protection • (78 biologics approved too recently to determine if additional data protection would delay biosimilars) • 16 biologics with expired data protection • 5 potentially would have been affected by additional data protection

  12. Bottom Line • Based on biologics currently on Canadian market • Potential impact on overall Canadian drug expenditures of a two-year extension in data protection is highly variable • No increase in spending to a $305.8 million over slightly more than two and a half years depending on the strength of patent protection and whether those patents are challenged in court.

More Related